Tau-targeting antibody therapies: too late, wrong epitope or wrong target?

Edwin Jabbari^{1

2}, Karen E Duff^{3

4}

Affiliations

¹ Department of Clinical and Movement Neurosciences, UCL Queen Square Institute of Neurology, London, UK. e.jabbari@ucl.ac.uk.
² Movement Disorders Centre, UCL Queen Square Institute of Neurology, London, UK. e.jabbari@ucl.ac.uk.
³ Department of Pathology and Cell Biology, Columbia University Irving Medical Center, New York, NY, USA. k.duff@ucl.ac.uk.
⁴ UK Dementia Research Institute, University College London, London, UK. k.duff@ucl.ac.uk.

Comment

Edwin Jabbari et al. Nat Med. 2021 Aug.

. 2021 Aug;27(8):1341-1342.

doi: 10.1038/s41591-021-01465-9.

Edwin Jabbari^{1

2}, Karen E Duff^{3

4}

¹ Department of Clinical and Movement Neurosciences, UCL Queen Square Institute of Neurology, London, UK. e.jabbari@ucl.ac.uk.
² Movement Disorders Centre, UCL Queen Square Institute of Neurology, London, UK. e.jabbari@ucl.ac.uk.
³ Department of Pathology and Cell Biology, Columbia University Irving Medical Center, New York, NY, USA. k.duff@ucl.ac.uk.
⁴ UK Dementia Research Institute, University College London, London, UK. k.duff@ucl.ac.uk.

No abstract available

Comment on

Safety and efficacy of tilavonemab in progressive supranuclear palsy: a phase 2, randomised, placebo-controlled trial.
Höglinger GU, Litvan I, Mendonca N, Wang D, Zheng H, Rendenbach-Mueller B, Lon HK, Jin Z, Fisseha N, Budur K, Gold M, Ryman D, Florian H; Arise Investigators. Höglinger GU, et al. Lancet Neurol. 2021 Mar;20(3):182-192. doi: 10.1016/S1474-4422(20)30489-0. Lancet Neurol. 2021. PMID: 33609476 Clinical Trial.
Safety and efficacy of anti-tau monoclonal antibody gosuranemab in progressive supranuclear palsy: a phase 2, randomized, placebo-controlled trial.
Dam T, Boxer AL, Golbe LI, Höglinger GU, Morris HR, Litvan I, Lang AE, Corvol JC, Aiba I, Grundman M, Yang L, Tidemann-Miller B, Kupferman J, Harper K, Kamisoglu K, Wald MJ, Graham DL, Gedney L, O'Gorman J, Haeberlein SB; PASSPORT Study Group. Dam T, et al. Nat Med. 2021 Aug;27(8):1451-1457. doi: 10.1038/s41591-021-01455-x. Epub 2021 Aug 12. Nat Med. 2021. PMID: 34385707 Clinical Trial.